These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 6538824)

  • 1. Influence of pharmacokinetic diurnal variation on bioavailability estimates.
    Bauer LA; Gibaldi M; Vestal RE
    Clin Pharmacokinet; 1984; 9(2):184-7. PubMed ID: 6538824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of single and multiple dose pharmacokinetics of theophylline using stable isotopes.
    Vestal RE; Thummel KE; Mercer GD; Koup JR
    Eur J Clin Pharmacol; 1986; 30(1):113-20. PubMed ID: 3709624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic properties of a new sustained-release theophylline preparation.
    Dahlqvist R; Billing B
    Int J Clin Pharmacol Ther Toxicol; 1983 Feb; 21(2):69-72. PubMed ID: 6840927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of theophylline and bioavailability of a sustained release theophylline preparation in patients with cystic fibrosis.
    Valet SB; Schwartz RH; Brooks JG
    Ann Allergy; 1983 Mar; 50(3):161-5. PubMed ID: 6829982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacolinetic and pharmacodynamic data analysis of theophylline for three different drug forms.
    Richter O; Reinhardt D; Appel R
    Int J Clin Pharmacol Ther Toxicol; 1981 Nov; 19(11):479-89. PubMed ID: 6271690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Night-time pharmacokinetics of once a day theophylline: a steady state comparison of three preparations.
    Karttunen P; Tukiainen H; Nykänen S; Saano V
    Int J Clin Pharmacol Ther Toxicol; 1985 Mar; 23(3):161-5. PubMed ID: 3997302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Theophylline bioavailability: a comparison of the oral absorption of a theophylline elixir and two combination theophylline tablets to intravenous aminophylline.
    Fixley M; Shen DD; Azarnoff DL
    Am Rev Respir Dis; 1977 Jun; 115(6):955-62. PubMed ID: 262107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose-dependent kinetics of theophylline.
    Lesko LJ
    J Allergy Clin Immunol; 1986 Oct; 78(4 Pt 2):723-7. PubMed ID: 3534053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pharmacokinetics of theophylline and circadian rhythm].
    Pradalier A; Dry J; Flouvat B; Decourt S; Fodor F
    Pathol Biol (Paris); 1982 Dec; 30(10):851-4. PubMed ID: 6760063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absorption of theophylline from conventional and sustained-release tablets.
    Fagerström PO; Mellstrand T; Svedmyr N
    Int J Clin Pharmacol Ther Toxicol; 1981 Mar; 19(3):131-8. PubMed ID: 7228455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A clinical and pharmacokinetic basis for the selection and use of slow release theophylline products.
    Hendeles L; Iafrate RP; Weinberger M
    Clin Pharmacokinet; 1984; 9(2):95-135. PubMed ID: 6370542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioavailability of theophylline from a sustained-release aminophylline formulation (Euphyllin retard tablets)--plasma levels after single and multiple oral doses.
    Schuppan D; Molz KH; Staib AH; Rietbrock N
    Int J Clin Pharmacol Ther Toxicol; 1981 May; 19(5):223-7. PubMed ID: 7251238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is a diurnal rhythm in bioavailability caused by a rhythm in intestinal absorption?
    Tukker JJ; Meulendijk AJ
    Eur J Drug Metab Pharmacokinet; 1991; Spec No 3():66-70. PubMed ID: 1820938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Bioavailability of a delayed-action aminophylline preparation].
    Regazzi MB; Guarnone E; Bartoli A; Ciardelli L; Piacentini P
    Minerva Med; 1985 Mar; 76(13):641-5. PubMed ID: 3991030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Bioavailability of 3 theophylline delayed-release preparations. Comparison of theophylline concentrations in the serum and saliva in the steady state].
    Bochsler HP; Meyer UA
    Schweiz Med Wochenschr; 1982 Nov; 112(47):1702-10. PubMed ID: 7178872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of aminophylline and theophylline sustained-release formulations by their bioavailability and steady-state serum levels.
    Steinijans VW; Zech K; Fischer R
    Int J Clin Pharmacol Ther Toxicol; 1983 Dec; 21(12):624-30. PubMed ID: 6668100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Euphylong in standard dosage: comparison with an international retard preparation for twice-daily administration in recommended dosage].
    Siemon G; Huber W; Maier-Stocker P
    Pneumologie; 1991 Nov; 45 Suppl 4():853-7. PubMed ID: 1812479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioavailability and multiple dose characteristics of a new sustained release theophylline tablet.
    Spangler DL; Vanderpool GE; Carroll MS; Tinkelman DG
    Ann Allergy; 1980 Dec; 45(6):355-9. PubMed ID: 7447084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diurnal variation in valproic acid clearance.
    Bauer LA; Davis R; Wilensky A; Raisys V; Levy RH
    Clin Pharmacol Ther; 1984 Apr; 35(4):505-9. PubMed ID: 6423338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of cefixime after oral and intravenous doses in dogs: bioavailability assessment for a drug showing nonlinear serum protein binding.
    Bialer M; Wu WH; Look ZM; Silber BM; Yacobi A
    Res Commun Chem Pathol Pharmacol; 1987 Apr; 56(1):21-32. PubMed ID: 3589152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.